Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options

Phosphorylation of PAX3 contributes to melanoma phenotypes by affecting proliferation, invasion, and transformation

(2014) Aditi S. Iyengar et al.   Pigment Cell & Melanoma Research

Glycogen synthase kinase 3 inhibitors induce the canonical WNT/ -catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma

(2014) E. Y. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glycogen synthase kinase 3β represses MYOGENIN function in alveolar rhabdomyosarcoma

(2014) M G Dionyssiou et al.   Cell Death & Disease

Lithium Chloride and Inhibition of Glycogen Synthase Kinase 3β as a Potential Therapy for Serous Ovarian Cancer

(2013) Akiva P. Novetsky et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group

(2013) Brenda Weigel et al.   PEDIATRIC BLOOD & CANCER

Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls

(2013) Ashley R. P. Hinson et al.   Frontiers in Oncology

Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas

(2012) P. G. Casali   ANNALS OF ONCOLOGY

Identification of CK2 as the kinase that phosphorylates Pax3 at Ser209 in early myogenic differentiation

(2012) Aditi S. Iyengar et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

P-cadherin is a direct PAX3–FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness

(2012) S Thuault et al.   ONCOGENE

Phase 1 clinical trials for sarcomas: the cutting edge

(2011) Vivek Subbiah et al.   CURRENT OPINION IN ONCOLOGY

Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation

(2011) Kevin N. Dietz et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib

(2011) Juan Manuel Domínguez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling

(2010) Bin Fang et al.   BIOCHEMICAL PHARMACOLOGY

Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y

(2010) Ayhan Bilir et al.   JOURNAL OF NEURO-ONCOLOGY

Glycogen synthase kinase 3 regulates PAX3–FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells

(2009) Fu-Yue Zeng et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Phosphorylation of Serine 205 by the Protein Kinase CK2 Persists on Pax3-FOXO1, but Not Pax3, throughout Early Myogenic Differentiation

(2009) Kevin N. Dietz et al.   BIOCHEMISTRY

Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005

(2009) Simona Ognjanovic et al.   CANCER

PAX3–FOXO1 fusion gene in rhabdomyosarcoma

(2008) Corinne M. Linardic   CANCER LETTERS

Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy

(2008) Jia Luo   CANCER LETTERS

Phosphorylation Regulates Transcriptional Activity of PAX3/FKHR and Reveals Novel Therapeutic Possibilities

(2008) R. Amstutz et al.   CANCER RESEARCH

Identification of serine 205 as a site of phosphorylation on Pax3 in proliferating but not differentiating primary myoblasts

(2008) Patrick J. Miller et al.   PROTEIN SCIENCE

Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma

(2007) Ken Kikuchi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS